ZA200306333B - Bifunctional fusion proteins with Glucocerebrosidase activity. - Google Patents

Bifunctional fusion proteins with Glucocerebrosidase activity.

Info

Publication number
ZA200306333B
ZA200306333B ZA200306333A ZA200306333A ZA200306333B ZA 200306333 B ZA200306333 B ZA 200306333B ZA 200306333 A ZA200306333 A ZA 200306333A ZA 200306333 A ZA200306333 A ZA 200306333A ZA 200306333 B ZA200306333 B ZA 200306333B
Authority
ZA
South Africa
Prior art keywords
fusion proteins
bifunctional fusion
glucocerebrosidase activity
glucocerebrosidase
activity
Prior art date
Application number
ZA200306333A
Other languages
English (en)
Inventor
Silke Schumacher
Stephen Gillies
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of ZA200306333B publication Critical patent/ZA200306333B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ZA200306333A 2001-01-18 2003-08-14 Bifunctional fusion proteins with Glucocerebrosidase activity. ZA200306333B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01101056 2001-01-18

Publications (1)

Publication Number Publication Date
ZA200306333B true ZA200306333B (en) 2004-11-17

Family

ID=8176235

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200306333A ZA200306333B (en) 2001-01-18 2003-08-14 Bifunctional fusion proteins with Glucocerebrosidase activity.

Country Status (13)

Country Link
US (1) US20040043457A1 (xx)
EP (1) EP1392826A2 (xx)
JP (1) JP2004525621A (xx)
KR (1) KR20030067755A (xx)
CN (1) CN1630720A (xx)
BR (1) BR0116803A (xx)
CA (1) CA2435037A1 (xx)
HU (1) HUP0401300A3 (xx)
MX (1) MXPA03006294A (xx)
NO (1) NO20033247D0 (xx)
PL (1) PL362394A1 (xx)
WO (1) WO2002057435A2 (xx)
ZA (1) ZA200306333B (xx)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2221717T3 (es) 1997-12-08 2005-01-01 Emd Lexigen Research Center Corp. Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general.
ES2267263T3 (es) * 1998-04-15 2007-03-01 Emd Lexigen Research Center Corp. Coadministracion de un inhibidor de la angiogenesis para reforzar la respuesta inmunologica por medio de la mediacion de una proteina de fusion de una citoquina con un anticuerpo.
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
CN1235911C (zh) * 1999-08-09 2006-01-11 利思进药品公司 多细胞因子－抗体复合物
US20050202538A1 (en) * 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
AU4314801A (en) 2000-02-11 2001-08-20 Lexigen Pharm Corp Enhancing the circulating half-life of antibody-based fusion proteins
AU7172901A (en) * 2000-06-29 2002-01-14 Lexigen Pharm Corp Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
PT1366067E (pt) * 2001-03-07 2012-11-29 Merck Patent Gmbh Tecnologia de expressão para proteínas contendo uma unidade de anticorpo de isotipo híbrido
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
MXPA03009924A (es) * 2001-05-03 2004-01-29 Merck Patent Gmbh Anticuerpo recombinante especifico de tumor y uso del mismo.
ES2381025T3 (es) * 2001-12-04 2012-05-22 Merck Patent Gmbh Inmunocitocinas con selectividad modulada
WO2004055056A1 (en) * 2002-12-17 2004-07-01 Merck Patent Gmbh Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
US20050069521A1 (en) * 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
US7736653B2 (en) 2003-11-13 2010-06-15 Hanmi Pharm. Co., Ltd Pharmaceutical composition comprising an immunoglobulin Fc region as a carrier
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
WO2005063820A2 (en) 2003-12-30 2005-07-14 Merck Patent Gmbh Il-7 fusion proteins
CN1902222A (zh) * 2003-12-31 2007-01-24 默克专利有限公司 具有改善药物代谢动力学的Fc－促红细胞生成素融合蛋白质
DK1706428T3 (da) 2004-01-22 2009-11-30 Merck Patent Gmbh Anti-cancer-antistoffer med reduceret komplementfiksering
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
CA2591297C (en) * 2004-12-09 2015-01-13 Stephen D. Gillies Il-7 variants with reduced immunogenicity
WO2007012188A1 (en) * 2005-07-27 2007-02-01 Qinghua Wang GLP/1/EXENDM 4 IgG Fc FUSION CONSTRUCTS FOR TREATMENT OF DIABETES
JP2007063225A (ja) * 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
EP1948614A2 (en) * 2005-11-18 2008-07-30 Takeda San Diego, Inc. Glucokinase activators
WO2007076933A1 (en) 2005-12-30 2007-07-12 Merck Patent Gmbh Interleukin-12p40 variants with improved stability
ES2426468T3 (es) 2005-12-30 2013-10-23 Merck Patent Gmbh Anticuerpos anti-CD19 con inmunogenicidad reducida
PT1986612E (pt) 2006-02-07 2012-11-06 Shire Human Genetic Therapies Composição estável de glucocerebrosidase
US8034822B2 (en) 2006-03-08 2011-10-11 Takeda San Diego, Inc. Glucokinase activators
WO2008054544A2 (en) * 2006-05-22 2008-05-08 Immune Disease Institute, Inc. Method for delivery across the blood brain barrier
WO2007143434A2 (en) 2006-05-31 2007-12-13 Takeda San Diego, Inc. Indazole and isoindole derivatives as glucokinase activating agents
JP5419706B2 (ja) 2006-12-20 2014-02-19 タケダ カリフォルニア インコーポレイテッド グルコキナーゼアクチベーター
WO2008116107A2 (en) * 2007-03-21 2008-09-25 Takeda San Diego, Inc. Piperazine derivatives as glucokinase activators
US8742079B2 (en) 2007-08-20 2014-06-03 Protalix Ltd. Saccharide-containing protein conjugates and uses thereof
CA2759333A1 (en) * 2009-04-22 2010-10-28 Merck Patent Gmbh Antibody fusion proteins with modified fcrn binding sites
US8889621B2 (en) 2009-10-30 2014-11-18 New York University Inhibiting binding of FGF23 to the binary FGFR-Klotho complex for the treatment of hypophosphatemia
US9194011B2 (en) 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
PE20121337A1 (es) * 2009-11-27 2012-10-12 Genzyme Corp Forma cristalina y amorfa de hemitartrato de genz 112638 como inhibidor de glucosilceramida sintasa
WO2011107992A2 (en) * 2010-03-02 2011-09-09 Protalix Ltd. Multimeric forms of therapeutic proteins and uses thereof
PL3272861T3 (pl) 2011-01-20 2020-07-13 Protalix Ltd. Kompozycje alfa- galaktozydazy
US9657075B2 (en) 2012-06-07 2017-05-23 New York University Chimeric fibroblast growth factor 23 proteins and methods of use
WO2014130659A1 (en) 2013-02-22 2014-08-28 New York University Chimeric fibroblast growth factor 23 proteins and methods of use
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
JOP20140087B1 (ar) 2013-03-13 2021-08-17 Amgen Inc بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
WO2015009052A1 (ko) * 2013-07-16 2015-01-22 일동제약 주식회사 하이브리드 면역글로불린 fc와 효소의 융합단백질
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
CN106456714A (zh) * 2014-03-28 2017-02-22 纽约大学 Fgf23融合蛋白
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
IL271837B2 (en) * 2017-07-07 2024-01-01 Hanmi Pharm Ind Co Ltd A new medical fusion protein with an enzyme and its uses

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US6475486B1 (en) * 1990-10-18 2002-11-05 Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
US5650150A (en) * 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
AU5065198A (en) * 1996-11-15 1998-06-10 Maria Grazia Masucci Fusion proteins having increased half-lives
WO1998046257A1 (en) * 1997-04-17 1998-10-22 Amgen Inc. Compositions comprising conjugates of stable, active, human ob protein with antibody fc chain and methods
US6395299B1 (en) * 1999-02-12 2002-05-28 Biostream, Inc. Matrices for drug delivery and methods for making and using the same
IL151024A0 (en) * 2000-02-15 2003-02-12 Genzyme Corp Conjugates of a biopolymer and a therapeutic agent
DE10102053A1 (de) * 2001-01-17 2002-07-18 Merck Patent Gmbh Piperazinylcarbonylchinoline und -isochinoline

Also Published As

Publication number Publication date
MXPA03006294A (es) 2003-09-16
EP1392826A2 (en) 2004-03-03
NO20033247L (no) 2003-07-17
KR20030067755A (ko) 2003-08-14
PL362394A1 (en) 2004-11-02
JP2004525621A (ja) 2004-08-26
NO20033247D0 (no) 2003-07-17
CA2435037A1 (en) 2002-07-25
BR0116803A (pt) 2004-02-17
WO2002057435A2 (en) 2002-07-25
WO2002057435A3 (en) 2003-12-24
HUP0401300A2 (hu) 2004-09-28
US20040043457A1 (en) 2004-03-04
CN1630720A (zh) 2005-06-22
HUP0401300A3 (en) 2005-06-28

Similar Documents

Publication Publication Date Title
ZA200306333B (en) Bifunctional fusion proteins with Glucocerebrosidase activity.
AU2002300734A1 (en) Fusion protein having enhanced in vivo erythropoietin activity
HK1052037A1 (en) Structural member.
MXPA01013362A (es) Anticuerpos de humano, anti-alfavbeta3 recombinantes, °cidos nucleicos que codifican a los mismos y metodos de uso.
MXPA03007323A (es) Proteinas artificiales con inmunogenicidad reducida.
ZA200105484B (en) Polypeptide variants with altered effector function.
ZA200200477B (en) 2-pyrazolin-5-ones.
EG24361A (en) 4-pyrimiding1-n-acy1.l.phenlalanines
GB2361323B (en) Goggles assembly
ZA200202537B (en) Pour-on-formulations.
HK1051153A1 (en) Toy figure.
ZA200206172B (en) Fusion protein having enhanced in vivo activity of erythropoietin.
ZA200203762B (en) 4-pyridinyl-IN-acyl-L-phenylalanines.
HK1029502A1 (en) Slider-pull-assembling unit.
MXPA03009167A (es) PRODUCTO ABSORBENTE CON ADAPTACIoN MEJORADA.
ZA200108646B (en) Electrodes.
GB9913437D0 (en) Fusion proteins
HK1032814A1 (en) Absorber.
HK1032254A1 (en) Hinge assembly.
ZA200200263B (en) Drive.
MXPA03001951A (es) Pirroliminas y pirazoliminas fusionadas substituidas.
EP1392204A4 (en) BIFUNCTIONAL ENERGY REVERSIBLE ACYL COMPOSITIONS
ZA992018B (en) Banners.
ZA200108160B (en) Swing drive assembly.
HK1031254A1 (en) Tachogragh.